Mavrilimumab (CAM-3001) is a investigational human IgG4 monoclonal antibody targeting the GM-CSF receptor alpha, currently under development for the treatment of rheumatoid arthritis (RA); GM-CSF plays a central role in the pathogenesis of RA by promoting activation, differentiation, and survival of macrophages and neutrophils.